Short answer
Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on November 2, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Syndax Pharmaceuticals Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Press release and investor presentation furnished as Exhibits 99.1 and 99.2
- Results announcement directs investors to the exhibits for financial performance details
Item 5.02 · Departure/Election of Directors or Officers
- CFO Keith Goldan retires November 9, 2026, remaining temporarily as an advisor at materially consistent compensation
- Aaron Ondrey becomes CFO, principal accounting and financial officer, and treasurer on November 9, 2026
- Ondrey compensation: $543,000 base salary, 45% target bonus, and option for 270,000 shares
- Option vesting: 25% after one year, remainder monthly over 36 months, subject to continued service
- Employment protections include nine months’ severance, expanding to 18 months plus bonus and full equity acceleration after a qualifying change in control
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $83.3M, up 82% year over year, driven by Revuforj revenue $60.7M and collaboration revenue $22.6M
- Revuforj revenue rose 90% year over year and 11% sequentially, with new patients up approximately 20% sequentially
- Niktimvo net revenue $67.4M, up 47% year over year, generating Syndax collaboration revenue of $22.6M
- Net loss narrowed to $49.4M, or $0.55 per share, from $60.7M, or $0.70 per share
- Cash, equivalents and investments $551.1M, while management maintained 2026 operating-expense guidance of approximately $400M and expects profitability with revenue growth
Item EX-99.2 · Exhibit EX-99.2
- 3Q26 total revenue $83.3M, up from $45.9M, driven by Revuforj product revenue $60.7M and Niktimvo collaboration revenue $22.6M
- Revuforj net revenue grew 90% year over year and 11% quarter over quarter, with approximately 1,700 prescriptions and approximately 300 new patient starts
- Niktimvo collaboration revenue rose 63% year over year to $22.6M, supporting annualized collaboration revenue above $90M
- Net loss narrowed to $49.4M from $60.7M, while cash and equivalents totaled $551.1M as of September 30, 2026
- Near-term catalysts include frontline AML data in 4Q26, an SNDX-4321 IND by year-end 2026, and four pipeline assets expected in clinical development during 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Syndax Pharmaceuticals Inc 8-K filings
Get the next SNDX 8-K as it lands
Follow SNDX for push alerts, or ask the research agent what this filing means.